83 related articles for article (PubMed ID: 9301456)
1. TP53 mutation in ovarian carcinoma.
Murphy M; McManus DT; Toner PG; Russell SE
Eur J Cancer; 1997 Jul; 33(8):1281-3. PubMed ID: 9301456
[TBL] [Abstract][Full Text] [Related]
2. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
4. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
5. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
Niwa K; Itoh M; Murase T; Morishita S; Itoh N; Mori H; Tamaya T
Br J Cancer; 1994 Dec; 70(6):1191-7. PubMed ID: 7981076
[TBL] [Abstract][Full Text] [Related]
6.
Na K; Sung JY; Kim HS
Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
[TBL] [Abstract][Full Text] [Related]
8. Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation.
Wong C; DiCioccio RA; Allen HJ; Werness BA; Piver MS
Cancer Genet Cytogenet; 1998 Nov; 107(1):21-7. PubMed ID: 9809029
[TBL] [Abstract][Full Text] [Related]
9. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
[TBL] [Abstract][Full Text] [Related]
11. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.
Skomedal H; Kristensen GB; Abeler VM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1997 Feb; 181(2):158-65. PubMed ID: 9120719
[TBL] [Abstract][Full Text] [Related]
12. Expression signatures of TP53 mutations in serous ovarian cancers.
Bernardini MQ; Baba T; Lee PS; Barnett JC; Sfakianos GP; Secord AA; Murphy SK; Iversen E; Marks JR; Berchuck A
BMC Cancer; 2010 May; 10():237. PubMed ID: 20504346
[TBL] [Abstract][Full Text] [Related]
13. Analytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections.
Marton MJ; McNamara AR; Nikoloff DM; Nakao A; Cheng J
PLoS One; 2015; 10(6):e0131497. PubMed ID: 26125596
[TBL] [Abstract][Full Text] [Related]
14. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffin-embedded tissue.
Hayes VM; Bleeker W; Verlind E; Timmer T; Karrenbeld A; Plukker JT; Marx MP; Hofstra RM; Buys CH
Diagn Mol Pathol; 1999 Mar; 8(1):2-10. PubMed ID: 10408787
[TBL] [Abstract][Full Text] [Related]
16. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
17. Geographical variations in TP53 mutational spectrum in ovarian carcinomas.
Dansonka-Mieszkowska A; Ludwig AH; Kraszewska E; Kupryjańczyk J
Ann Hum Genet; 2006 Sep; 70(Pt 5):594-604. PubMed ID: 16907706
[TBL] [Abstract][Full Text] [Related]
18. Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.
Ardighieri L; Mori L; Conzadori S; Bugatti M; Falchetti M; Donzelli CM; Ravaggi A; Odicino FE; Facchetti F
Virchows Arch; 2016 Jul; 469(1):61-9. PubMed ID: 27059324
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands.
Schuyer M; Henzen-Logmans SC; van der Burg ME; Fieret EJ; Klijn JG; Foekens JA; Berns EM
Int J Cancer; 1998 May; 76(3):299-303. PubMed ID: 9579562
[TBL] [Abstract][Full Text] [Related]
20. Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue.
Crobach S; Ruano D; van Eijk R; Fleuren GJ; Minderhout I; Snowdowne R; Tops C; van Wezel T; Morreau H
J Mol Diagn; 2015 Mar; 17(2):193-200. PubMed ID: 25545608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
